Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer

Medicine
Deyuan FuJiaxin Zhang

Abstract

Aberrant DNA methylation that leads to the inactivation of tumor suppressor genes is known to play an important role in the development and progression of breast cancer. Methylation status of cancer-related genes is considered to be a promising biomarker for the early diagnosis and prognosis of tumors. This study investigated the methylation status of the Sox17 gene in breast cancer tissue and its corresponding plasma DNA to evaluate the association of methylation levels with clinicopathological parameters and prognosis.The methylation status of the Sox17 gene promoter was evaluated with methylation-specific polymerase chain reaction (MSP) in 155 paired breast cancer tissue and plasma samples and in 60 paired normal breast tissue and plasma samples. Association of Sox17 methylation status with clinicopathological parameters was analyzed by χ tests. Overall and disease-free survival (DFS) curves were calculated using Kaplan-Meier analysis, and the differences between curves were analyzed by log-rank tests.The frequency of Sox17 gene methylation was 72.9% (113/155) in breast cancer tissues and 58.1% (90/155) in plasma DNA. Sox17 gene methylation was not found in normal breast tissues or in their paired plasma DNA. There was a sig...Continue Reading

References

Oct 3, 1999·Cancer Metastasis Reviews·P AnkerM Stroun
Feb 13, 2002·The American Journal of Pathology·Ulrich LehmannHans Kreipe
Aug 3, 2002·Oncogene·Martin Widschwendter, Peter A Jones
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Partha M Das, Rakesh Singal
Sep 22, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jiho SohnVittorio Gallo
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pearlly S YanTim H-M Huang
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yu LiuMichael D Schneider
Apr 28, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Anshu AgrawalDevendra K Agrawal
Oct 7, 2008·The International Journal of Biochemistry & Cell Biology·Jingde Zhu, Xuebiao Yao
Oct 1, 2009·Nature Reviews. Genetics·Peter A Jones, Gangning Liang
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Thomas E LiggettVictor V Levenson
Aug 19, 2010·Epigenetics : Official Journal of the DNA Methylation Society·Yan JiaMingzhou Guo
Jan 12, 2011·Breast Cancer Research and Treatment·Georg GöbelGünter Daxenbichler
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Mar 3, 2011·Nature Reviews. Clinical Oncology·Samir M HanashOlli Kallioniemi
Apr 26, 2011·Cancer Letters·Yan-Wei YeYing-Qiang Shi
Oct 1, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Li-Jin ChewVittorio Gallo
Dec 14, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yoshichika OishiFumio Itoh
Apr 25, 2012·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Michail IgnatiadisKlaus Pantel
Dec 18, 2012·The Journal of Clinical Investigation·Hanseul YangInjune Kim
Feb 14, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Ioanna BalgkouranidouStylianos Kakolyris
Jan 11, 2014·International Journal of Cancer. Journal International Du Cancer·I-Ying KuoYi-Ching Wang

❮ Previous
Next ❯

Citations

Feb 18, 2016·Clinical Epigenetics·Elizaveta V BenevolenskayaGarth H Rauscher
Jan 15, 2016·Endocrine-related Cancer·Kristina WartonGoli Samimi
Oct 11, 2015·Breast Cancer Research : BCR·Heidi Schwarzenbach, Klaus Pantel
Aug 12, 2016·Clinica Chimica Acta; International Journal of Clinical Chemistry·C ParisiE S Lianidou
Jul 28, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zibo LiJun Wang
Jun 30, 2016·PloS One·Rubiceli Medina-AguilarCésar López-Camarillo
May 14, 2017·International Journal of Cancer. Journal International Du Cancer·Megan A ClarkeNicolas Wentzensen
Apr 7, 2017·Journal of breast cancer·Isabella Wai Yin CheukAva Kwong
Jan 11, 2019·Journal of Toxicology and Environmental Health. Part a·Jin WangJian-Xiang Li
Jun 13, 2020·Cell Proliferation·Ziyu HeWen Li
May 10, 2019·Journal of Mammary Gland Biology and Neoplasia·Gaurav A MehtaMichael L Gatza
Aug 24, 2017·International Journal of Genomics·Jiwei XueMenglong Li
Aug 12, 2016·International Journal of Molecular Medicine·Wenli LiYuanlong He
Jul 3, 2021·Cancers·Cora Palanca-BallesterAlfonso Calvo

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.